Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GlaxoSmithKline : BioNTech aims to develop mRNA-based malaria vaccine

07/26/2021 | 11:53am EDT

(Corrects mRNA description in paragraph 6 to pathogen from virus)

* Plans to start clinical trial by end of 2022

* Malaria kills more than 400,000 people per year

* BioNTech explores vaccine production in Africa

BERLIN, July 26 (Reuters) - BioNTech wants to build on its success in COVID-19 by developing the first vaccine for malaria based on mRNA technology and aims to start clinical testing by the end on 2022, in an attempt to eradicate the mosquito-borne illness.

The Mainz, Germany-based company, which developed a COVID-19 vaccine with its partner Pfizer in ten months, said on Monday it is also exploring vaccine production in Africa as part of efforts to build up manufacturing capacity on the continent.

"The response to the pandemic has shown that science and innovation can transform people's lives when all key stakeholders work together towards a common goal," said BioNTech Chief Executive and co-founder Ugur Sahin.

Scientists around the world have been working for decades to develop a vaccine to prevent malaria that infects millions of people every year and kills more than 400,000 - most of them babies and young children in the poorest parts of Africa.

Malaria is a complex infection caused by a parasite that evades recognition by the immune system, said Sahin, adding the goal is to develop a vaccine that makes the parasite visible and attackable from the very beginning.

Messenger RNA vaccines prompt the human body to make a protein that is part of the pathogen, triggering an immune response. They are also quicker to develop than traditional vaccines and can be adapted relatively easily.

"The very high efficacy of two mRNA vaccines for COVID-19 have shown the world just how powerful this technology could be against many diseases, including malaria," said World Health Organisation (WHO) head Tedros Adhanom Ghebreyesus, who started his career as a malaria researcher.

The world's first and only licensed malaria vaccine, Mosquirix, was developed by GlaxoSmithKline over many years of clinical trial across several African countries, but is only around 30% effective.

Researchers at Oxford's Jenner Institute led by Adrian Hill, one of the lead scientists behind the Oxford-AstraZeneca COVID-19 vaccine, are also developing a potential new malaria vaccine that has shown promise in a year-long trial.

BioNTech said it will assess multiple vaccine candidates that target the circumsporozoite protein (CSP), as well as new antigens discovered in pre-clinical research and select the most promising for a clinical trial due to start by the end of 2022.

The company is also scouting for suitable mRNA vaccine production sites in Africa, either with partners or on its own, and will receive support from the European Commission, the Bill and Melinda Gates Foundation and other organisations.

BioNTech Chief Operating Officer Sierk Poetting said the company would fund the research and initial production of the vaccine itself and turn to its partners for support with large-scale trials, as well as setting up infrastructure, such as fill and finish sites and providing local training.

BioNTech also plans to start a clinical trial to test a vaccine candidate for tuberculosis in 2022 and is working with partners to develop vaccines against nine different infectious diseases as well as for cancer. (Reporting by Caroline Copley and Patricia Weiss; Editing by Bernadette Baum)

ę Reuters 2021
10:41aFDA grants Priority Review to ViiV Healthcare's New Drug Application for cabotegravir l..
08:34aSanofi drops vaccine bid amid rivals' success
08:13aSanofi ditches mRNA COVID-19 vaccine after rivals' success
07:44aGLAXOSMITHKLINE : ViiV Healthcare's New Drug Application for HIV Prevention Gets FDA Accep..
07:15aGLAXOSMITHKLINE : ViiV Healthcare Enters Into Exclusive Agreement With Shionogi for Potent..
06:12aGLAXOSMITHKLINE : FDA grants Priority Review to ViiV Healthcare's New Drug Application for..
05:57aViiV Gets FDA Priority Review for Cabotegravir Long-Acting for HIV Prevention
04:41aSANOFI : Abandons mRNA COVID-19 Jab To Focus On Flu, Other Diseases
03:51aSANOFI : Says Its COVID-19 Vaccine Candidate Demonstrates High Seroconversion in Phase 1/2..
02:57aSanofi to Halt MRNA Covid-19 Vaccine Development Despite Positive Trial Results -- Upda..
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Sales 2021 33 307 M 45 096 M 45 096 M
Net income 2021 3 857 M 5 222 M 5 222 M
Net Debt 2021 20 885 M 28 278 M 28 278 M
P/E ratio 2021 18,1x
Yield 2021 5,78%
Capitalization 69 218 M 93 752 M 93 720 M
EV / Sales 2021 2,71x
EV / Sales 2022 2,53x
Nbr of Employees 94 066
Free-Float 92,2%
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 1 383,00 GBX
Average target price 1 604,94 GBX
Spread / Average Target 16,0%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON3.45%429 542
ROCHE HOLDING AG9.24%319 352
PFIZER, INC.18.36%244 283
NOVO NORDISK A/S48.08%227 557